Cancers 2011, 3(2), 2444-2461; doi:10.3390/cancers3022444
Review

Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer

Carmen Berasain 1,* email, María Ujue Latasa 1 email, Raquel Urtasun 1 email, Saioa Goñi 1 email, María Elizalde 1 email, Oihane Garcia-Irigoyen 1 email, María Azcona 1 email, Jesús Prieto 1,2 email and Matías A. Ávila 1 email
1 Division of Hepatology and Gene Therapy, CIMA, University of Navarra, Pamplona 31008, Spain 2 CIBERehd, University Clinic, University of Navarra, Pamplona 31080, Spain
* Author to whom correspondence should be addressed.
Received: 20 April 2011; in revised form: 6 May 2011 / Accepted: 12 May 2011 / Published: 18 May 2011
(This article belongs to the Special Issue Cancer Signaling Pathways and Crosstalk)
PDF Full-text Download PDF Full-Text [360 KB, Updated Version, uploaded 19 May 2011 10:11 CEST]
The original version is still available [361 KB, uploaded 18 May 2011 11:45 CEST]
Abstract: Hepatocarcinogenesis is a complex multistep process in which many different molecular pathways have been implicated. Hepatocellular carcinoma (HCC) is refractory to conventional chemotherapeutic agents, and the new targeted therapies are meeting with limited success. Interreceptor crosstalk and the positive feedback between different signaling systems are emerging as mechanisms of targeted therapy resistance. The identification of such interactions is therefore of particular relevance to improve therapeutic efficacy. Among the different signaling pathways activated in hepatocarcinogenesis the epidermal growth factor receptor (EGFR) system plays a prominent role, being recognized as a “signaling hub” where different extracellular growth and survival signals converge. EGFR can be transactivated in response to multiple heterologous ligands through the physical interaction with multiple receptors, the activity of intracellular kinases or the shedding of EGFR-ligands. In this article we review the crosstalk between the EGFR and other signaling pathways that could be relevant to liver cancer development and treatment.
Keywords: G protein-coupled receptor (GPCR); a desintegrin and metalloprotease (ADAM); transactivation; growth factor receptor

Article Statistics

Click here to load and display the download statistics.

Cite This Article

MDPI and ACS Style

Berasain, C.; Ujue Latasa, M.; Urtasun, R.; Goñi, S.; Elizalde, M.; Garcia-Irigoyen, O.; Azcona, M.; Prieto, J.; Ávila, M.A. Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer. Cancers 2011, 3, 2444-2461.

AMA Style

Berasain C, Ujue Latasa M, Urtasun R, Goñi S, Elizalde M, Garcia-Irigoyen O, Azcona M, Prieto J, Ávila MA. Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer. Cancers. 2011; 3(2):2444-2461.

Chicago/Turabian Style

Berasain, Carmen; Ujue Latasa, María; Urtasun, Raquel; Goñi, Saioa; Elizalde, María; Garcia-Irigoyen, Oihane; Azcona, María; Prieto, Jesús; Ávila, Matías A. 2011. "Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer." Cancers 3, no. 2: 2444-2461.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert